Item 8.01 Other Events.

UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549~~STATES

~~FORM~~SECURITIES ~~8-K~~AND EXCHANGE COMMISSION

~~CURRENT~~WASHINGTON, ~~REPORT~~D.C. 20549

~~Pursuant~~FORM ~~to Section 13 or 15(d) of the Securities Exchange Act of 1934~~8-K

~~Date~~CURRENT ~~of Report (Date of earliest event reported): October 07, 2025~~REPORT

~~Clearside~~Pursuant ~~Biomedical,~~to ~~Inc.~~Section 13 or 15(d)

~~(Exact name~~ of ~~Registrant~~the asSecurities ~~Specified~~Exchange inAct ~~Its~~of ~~Charter)~~1934

Delaware	001-37783	45-2437375
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
900 North Point ParkwaySuite 200
Alpharetta, Georgia		30005
(Address of Principal Executive Offices)		(Zip Code)

Date of Report (Date of earliest event reported): November 23, 2025

~~Registrant’s~~Clearside ~~Telephone Number~~Biomedical, ~~Including Area Code: (678) 270-3631~~Inc.

(~~Former~~Exact ~~Name~~name orof ~~Former~~Registrant ~~Address,~~as ifSpecified ~~Changed~~in ~~Since~~Its ~~Last Report~~Charter)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Delaware

001-37783

45-2437375

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


900 North Point Parkway Suite 200
Alpharetta, Georgia		30005
(Address of Principal Executive Offices)		(Zip Code)

~~☐Soliciting~~Registrant’s ~~material~~Telephone ~~pursuant~~Number, toIncluding ~~Rule~~Area ~~14a-12~~Code: ~~under the Exchange Act~~ (17678) ~~CFR 240.14a~~270-~~12)~~3631

~~☐Pre-commencement~~(Former ~~communications~~Name ~~pursuant~~or toFormer ~~Rule~~Address, ~~14d-2(b)~~if ~~under~~Changed ~~the~~Since ~~Exchange~~Last ~~Act (17 CFR 240.14d-2(b~~Report))

~~☐Pre~~Check the appropriate box below if the Form 8-~~commencement~~K ~~communications~~filing ~~pursuant~~is intended to ~~Rule~~simultaneously ~~13e-4(c)~~satisfy ~~under~~the filing obligation of the ~~Exchange~~registrant ~~Act~~under ~~(17~~any ~~CFR~~of ~~240.13e-4(c))~~the following provisions:

~~Securities~~☐ ~~registered~~Written communications pursuant to ~~Section~~Rule ~~12(b)~~425 ofunder the Securities Act: (17 CFR 230.425)

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CLSD		The Nasdaq Stock Market LLC

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~Indicate~~☐ byPre-commencement ~~check~~communications ~~mark~~pursuant ~~whether~~to ~~the registrant is an emerging growth company as defined in~~ Rule ~~405 of the Securities Act of 1933~~ 14d-2(~~§ 230.405 of this chapter~~b) orunder ~~Rule 12b-2 of~~ the ~~Securities~~ Exchange Act of(17 ~~1934~~CFR (§ 240.~~12b~~14d-2 ~~of this chapter~~(b). )

~~Emerging~~☐ ~~growth~~Pre-commencement ~~company~~communications ☐pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

IfSecurities anregistered ~~emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided~~ pursuant to Section 13 12(ab) of the ~~Exchange~~ Act~~. ☐~~:

Date: November 25, 2025

CLEARSIDE BIOMEDICAL, INC.

/s/ Charles A. Deignan

Charles A. Deignan

Chief Financial Officer

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

CLSD

The Nasdaq Stock Market LLC

OnIndicate ~~October~~by 6,check ~~2025,~~mark ~~Clearside~~whether ~~Biomedical, Inc. (~~the ~~“Company”)~~registrant ~~received~~is aan ~~letter~~emerging ~~from~~growth ~~the~~company ~~Nasdaq Hearings Panel (the “Panel”) notifying the Company that it has regained compliance with the Minimum Bid Price Requirement (~~as defined ~~below).~~in ~~Accordingly,~~Rule ~~the~~405 ~~Panel~~of ~~determined that~~ the ~~Company~~Securities ~~has~~Act ~~regained~~of ~~compliance~~1933 ~~with Nasdaq’s Listing Rules~~(§ 230.405 Toof ~~regain~~this ~~compliance~~chapter) ~~with~~or ~~the~~Rule ~~Minimum~~12b-2 ~~Bid~~of ~~Price Requirement,~~ the ~~Company’s~~Securities ~~common~~Exchange ~~stock~~Act ~~was~~of ~~required~~1934 to(§ 240.12b-2 ~~maintain a closing bid price~~ of ~~$1.00~~this ~~per share or more for at least 10 consecutive business days~~chapter).

AsEmerging ~~previously~~growth ~~disclosed,~~company on February 7, 2025, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was non-compliant with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). As the Company did not regain compliance with the Minimum Bid Price Requirement within the 180-calendar day grace period set forth by Listing Rule 5810(c)(3)(A) by August 6, 2025, Nasdaq notified the Company by letter dated August 11, 2025, that the Company’s securities are subject to delisting from Nasdaq unless the Company timely requested a hearing before a Panel. ☐

~~The~~If ~~Company~~an ~~submitted~~emerging agrowth ~~timely request for a hearing before the Panel~~company, ~~which~~indicate ~~automatically~~by ~~stayed~~check ~~any~~mark ~~suspension~~if ~~or delisting of~~ the ~~Company’s~~registrant ~~securities.~~has Onelected ~~September~~not ~~16,~~to ~~2025,~~use the ~~Company~~extended ~~attended~~transition ~~its~~period ~~hearing~~for ~~before~~complying ~~the Panel, during which it presented its plan to regain compliance~~ with ~~the~~any ~~Minimum~~new ~~Bid~~or ~~Price~~revised ~~Requirement,~~financial ~~which~~accounting ~~included~~standards ~~the~~provided ~~implementation~~pursuant ofto Section 13(a) ~~stockholder-approved~~of ~~reverse stock split effective on September 12, 2025. As noted above, this matter is now closed since~~ the ~~Company~~Exchange ~~is now compliant with all applicable Nasdaq continued listing rules~~Act. ☐

~~SIGNATURES~~Item 1.03. Bankruptcy or Receivership.

~~Pursuant~~On November 23, 2025, Clearside Biomedical, Inc. (the “Company”) filed a voluntary petition (Case No. 25-12109) for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such case, the “Case”). The Company will continue to operate its business as a “debtor-in-possession” under the ~~requirements~~jurisdiction of the ~~Securities~~Court ~~Exchange~~and ~~Act~~in accordance with the applicable provisions of ~~1934~~the Bankruptcy Code and orders of the Court. To ensure its ability to continue operating in the ordinary course of business, the ~~registrant~~Company has ~~duly~~filed ~~caused~~with ~~this~~the ~~report~~Court motions seeking a variety of “first-day” relief (collectively, the “First Day Motions”). The Company’s objective in the Case is to beconsummate ~~signed~~a onsale of substantially all of its ~~behalf~~assets byto the ~~undersigned~~highest ~~hereunto~~bidder. ~~duly~~Additional ~~authorized~~information about the Case, including access to Court documents, is available online at https://dm.epiq11.com/ClearsideBiomedical, a website administered by Epiq Bankruptcy Solutions LLC, a third-party bankruptcy claims and noticing agent. The information on this website is not incorporated by reference into, and does not constitute part of, this Current Report on Form 8-K.

Date: October 7, 2025	CLEARSIDE BIOMEDICAL, INC.
	By:	/s/ Charles A. Deignan
	Name:	Charles A. Deignan
	Title:	Chief Financial Officer

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 24, 2025, the Company received written notice (the “Delisting Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Case and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq has determined that the Company’s common stock, par value $0.001 per share (the “Common Stock”), will be delisted from Nasdaq. In addition, as previously disclosed, on August 28, 2025, the Company received written notice (the “MVLS Notice”) from Nasdaq notifying the Company that it is not in compliance with the minimum Market Value of Listed Securities of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A). In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, specifically referencing that certain MVLS Notice.

Trading of the Common Stock will be suspended at the opening of business on December 1, 2025 and a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Common Stock from listing on Nasdaq. The Delisting Notice also indicated that the Company may appeal Nasdaq’s determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.

The Company does not intend to appeal the determination and, therefore, it is expected that the Common Stock will be delisted. As a result, the Common Stock is expected to begin trading exclusively on the over-the-counter (“OTC”) market on December 1, 2025. On the OTC market, shares of the Common Stock, which previously traded on Nasdaq under the symbol CLSD is expected to trade under the symbol CLSDQ.

Item 7.01. Regulation FD Disclosure.

On November 24, 2025, the Company issued a press release announcing that it had entered into the Case. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits


Exhibit Number		Description

99.1		Press Release Dated November 24, 2025

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Filing Compare · Clearside Biomedical, Inc.